BridgeBio Pharma stock gains support as HC Wainwright trims earnings outlook but keeps buy rating
Published on 09/04/2026 at 17:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BridgeBio Pharma stock (ISIN US10806X1028) is trading at 75.41 USD as of September 4, 2026, according to market data compiled by MarketBeat and FXEmpire, after a volatile week that has drawn fresh analyst attention to the biotech’s earnings power and valuation.
Analyst adjusts earnings view but keeps bullish stance
According to a report summarized by MarketBeat on September 4, 2026, HC Wainwright has lowered its earnings estimates for BridgeBio Pharma for the coming periods, signaling expectations of weaker earnings versus its previous projections.
Despite the more cautious earnings trajectory, HC Wainwright reaffirmed a buy rating on BridgeBio and left its price target unchanged at 120.00 USD per share, implying upside of around 59 percent from the latest opening price of 75.41 USD stated in the same MarketBeat overview.
Stock performance and technical picture around 75 USD
The MarketBeat alert notes that shares of NASDAQ-listed BridgeBio opened at 75.41 USD on September 4, 2026, providing a clear reference point for investors tracking the stock’s current level.
A separate technical snapshot from FXEmpire’s BridgeBio technical analysis page lists the same closing price of 75.41 USD for the regular session and shows a pre market indication of 75.67 USD, confirming that the stock is trading slightly above its previous close as of the latest market data on September 4, 2026.
Further background on BridgeBio Pharma
For more regulatory filings, historic figures and detailed company information on BridgeBio Pharma, additional reports and data overviews are available.
Policy backdrop: US drug pricing agreements add context
BridgeBio’s broader operating environment is also shaped by US healthcare policy. A weekly checkup from the American Action Forum dated September 4, 2026 explains that the White House recently announced so called most favored nation pharmaceutical pricing agreements with nine additional manufacturers, including BridgeBio, alongside names such as Alcon, Astellas Pharma and Teva Pharmaceuticals. In total, these agreements now cover 26 companies that together represent an estimated 89 percent of the branded drug market, according to the American Action Forum analysis.
For investors in BridgeBio Pharma stock, these policy developments underscore that future pricing and reimbursement dynamics in the United States may be more tightly linked to international reference prices, which can influence long term revenue and margin trajectories across the branded drug portfolio.
Representative product focus in rare disease
BridgeBio Pharma focuses on genetically driven diseases, and a key representative product in its pipeline and partnered portfolio is the oncology medicine infigratinib, developed through its QED Therapeutics subsidiary for indications such as cholangiocarcinoma and achondroplasia. Sector commentary on rare disease competition highlights that BridgeBio has positioned infigratinib and other assets to compete with peers working on similar pathways, including efforts in conditions such as hypoparathyroidism, as noted in an Ascendis Pharma peer analysis that references BridgeBio’s activities.
Stock level and investor takeaway
With BridgeBio Pharma stock around 75.41 USD as of September 4, 2026 and a consensus average price target near 101.53 USD cited in the MarketBeat overview, the shares are trading well below the average analyst expectation, leaving a visible gap of roughly 26 USD between the current price and the consensus target.
BridgeBio Pharma stock at a glance
- Company: BridgeBio Pharma, Inc.
- ISIN: US10806X1028
- Ticker: BBIO
- Trading venue: NASDAQ
- Price (as of September 4, 2026): 75.41 USD
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: NASDAQ composite
